Memorial Sloan Kettering medical oncologist Michael Offin

Michael D. Offin, MD

Medical Oncologist

Clinical Expertise

Lung Cancer; Brain Metastases; Targeted Therapy for Lung Cancer; Clinical Trials

New Patient Appointments

Scheduling a visit is easy. Click below or call us to get started.

Accepted Insurance Providers

Dr. Offin accepts the following list of insurance providers. Select your insurance provider to see more details.

Contact and Location

Locations map

Find a Convenient Location

Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offers many services, including screening, chemotherapy, and medical testing.

About Me


MD, Rutgers University- New Jersey Medical School


Internal Medicine – Hospital of the University of Pennsylvania


Medical Oncology - Memorial Sloan Kettering Cancer Center

Board Certifications

Internal Medicine; Medical Oncology

I am a board-certified medical oncologist dedicated to caring for people with lung cancer. I have a particular interest in precision medicine techniques and treating people with lung cancer that has spread to the brain. As a member of the Brain Metastasis Clinical Center, I am part of a Disease Management Team of neurosurgeons, radiation oncologists, neurologists, and supportive care providers. Our goal is giving personalized care to people with lung cancer that has spread to the brain. I am an investigator in ongoing clinical trials studying novel ways to treat people with lung cancer. I see patients at the Rockefeller Outpatient Pavilion in Manhattan as well as at MSK Westchester in West Harrison, New York.

I am dedicated to caring for people with advanced lung cancer, including non-small cell lung cancer and small cell lung cancer. Finding out that you or a family member has lung cancer can be overwhelming. My team and I will help you understand your diagnosis and find the best path forward. I am devoted to providing the highest level of care, with the goal of providing personalized care to improve outcomes and quality of life. Together with a comprehensive team of cancer experts, I strive to ensure that all of my patients have individualized and exceptional care.

My research focuses on using laboratory findings to design clinical trials that further the care of people with lung cancer. With precision medicine and immunotherapy, people with lung cancer — including those with advanced disease, such as cancer that has spread to the brain — have many treatment and clinical trial options available. My goal, in research and when caring for patients, is to devise novel treatments. I aim to bring the discoveries made by our laboratory researchers to the bedside, for the benefit of those affected by advanced lung cancer.

My team and I will help you understand your diagnosis and find the best path forward.

Dr. Offin

Awards and Honors

  • Deans Award, Rutgers University
  • Alpha Omega Alpha member
  • Gold Humanism Honor Society member
  • Conquer Cancer Foundation ASCO Merit Award (2018)


Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

Clinical Trials

Smiling doctors in the lab

Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Research and Publications

View Dr. Offin's Lab

Offin M, Rizvi H, Tenet M, Ni A, Sanchez-Vega F, Li BT, Drilon A, Kris MG, Rudin CM, Schultz N, Arcila ME, Ladanyi M, Riely GJ, Yu H, Hellmann MD. Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers. Clin Cancer Res. 2018 Jul 25. doi: 10.1158/1078-0432.CCR-18-1102. PMID: 30045933.

Sabari JK, Offin M [co-first author], Stephens D, Ni A, Lee A, Pavlakis N, Clarke S, Diakos CI, Datta S, Tandon N, Martinez A, Myers ML, Makhnin A, Leger Y, Yu HA, Paik PK, Chaft JE, Kris MG, Jeon JO, Borsu LA, Ladanyi M, Arcila ME, Hernandez J, Henderson S, Shaffer T, Garg K, DiPasquo D, Raymond CK, Lim LP, Li M, Hellmann MD, Drilon A, Riely GJ, Rusch VW, Jones DR, Rimner A, Rudin CM, Isbell JM, Li BT. A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. J Natl Cancer Inst. 2018 Nov 28. doi: 10.1093/jnci/djy156. PMID: 30496436.

Suzawa K, Offin M [co-first author], Lu D, Kurzatkowski C, Vojnic M, Smith RS, Sabari JK, Tai H, Mattar M, Khodos I, de Stanchina E, Rudin CM, Kris MG, Arcila ME, Lockwood WW, Drilon A, Ladanyi M, Somwar R. Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer. Clin Cancer Res. 2018 Oct 23. doi: 10.1158/1078-0432.CCR-18-1640.PMID: 30352902.

Offin M, Liu D, Drilon A. Tumor-Agnostic Drug Development. Am Soc Clin Oncol Educ Book. 2018 May 23;(38):184-187. doi: 10.1200/EDBK_200831. PMID: 30231313.

Publications on PubMed

Visit PubMed for a full listing of Dr. Offin’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.